KyungDong Pharm home
Over-the-Counter Medicines

Dexidifen Syrup

Product Category
Antipyretic/pain reliever
Active Ingredients
Dexibuprofen
Appearance
White to light yellow suspension syrup with a unique scent in an opaque white bottle.
Reimbursement Code
648104031
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
In 100 mL
- Active ingredient: Dexibuprofen (in-house specification)----1.2g
- Additives (preservatives): Methyl paraoxybenzoate----30mg
Propyl paraoxybenzoate----20mg
- Other additives: concentrated glycerin, light kaolin, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, white sugar, pomegranate flavor SH09-0788, sucralose, citric acid,
Sodium citrate hydrate, xanthan gum, purified water, cherry flavor SC10-0945, polysorbate 80, DL-malic acid, D-sorbitol solution

2. Effectiveness
Fever caused by acute upper respiratory infection

3. Dosage and dosage
Children over 6 months of age: Take this drug at a dose of 0.4 to 0.6 mL/kg (5 to 7 mg/kg as dexibuprofen) at 4 to 6 hour intervals when necessary, not exceeding a maximum of 4 times a day (28 mg/kg).
For children weighing less than 30kg, the maximum dose should not exceed 25mL (300mg as dexibuprofen) per day.
Calculation formula for single dose (mL) = [body weight (kg) × (5 ~ 7mg)/kg] / (12mg/mL)
One dose of this medicine can be administered as follows depending on body weight or age.
(If you know your weight, it is more appropriate to take the dose according to your weight.)

※ Table: Refer to attached document

In a clinical trial (n=252) in which 5 mg/kg and 7 mg/kg of this drug were administered to pediatric patients with fever due to acute upper respiratory infection (axillary (armpit) temperature 38°C or higher), there was a tendency for a greater decrease in body temperature in the 7 mg/kg group than in the 5 mg/kg group, but this was not statistically significant.

4. Precautions for use
1. Warning
1) If a person who regularly drinks more than 3 cups of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms occur.
Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischemic heart disease, peripheral artery disease, or cerebrovascular disease should use dexibuprofen with careful consideration and avoid high-dose dexibuprofen (1200 mg per day). Additionally, patients with cardiovascular risk factors (e.g. hypertension, hyperlipidemia, diabetes, smoking) who require high doses of dexibuprofen (1200 mg per day) should be carefully considered before starting long-term treatment.
Clinical studies have shown that use of high doses (2400 mg per day) of ibuprofen may slightly increase the risk of arterial thrombosis (myocardial infarction or stroke). Overall, epidemiological studies have not demonstrated an association between low doses of ibuprofen (e.g., less than 1200 mg per day) and increased risk of arterial thrombotic events. Although there are limited data on the risk of arterial thrombosis with dexibuprofen, it is reasonable to assume that the risk of high-dose dexibuprofen (1200 mg per day) is similar to that of high-dose ibuprofen (2400 mg per day).
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.

2. Do not administer to the following patients
1) Peptic ulcer patients
2) Patients with severe blood abnormalities
3) Patients with severe liver impairment
4) Patients with severe renal impairment
5) Patients with severe cardiac dysfunction
6) Patients with severe high blood pressure
7) Patients with hypersensitivity to the ingredients of this drug
8) Patients with bronchial asthma or a history of it
9) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs.)
10) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)

3. Administer with caution to the following patients:
1) Patients with a history of peptic ulcer
2) Patients with blood abnormalities or a history thereof
3) Patients with bleeding tendencies (platelet dysfunction may occur)
4) Patients with hepatic impairment or its history
5) Patients with renal impairment or its history
6) Patients with cardiac dysfunction
7) Patients with high blood pressure
8) Patients with a history of hypersensitivity
9) Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)
10) Patients with ulcerative colitis
11) Crohn’s disease patient
12) Elderly and children
13) Stomach cancer patient
14) People taking low-dose aspirin for the purpose of preventing myocardial infarction or stroke (This drug may reduce the effectiveness of aspirin and increase the risk of severe gastrointestinal adverse reactions.)
Laboratory data have shown that ibuprofen can inhibit the platelet aggregation effect of low-dose aspirin when administered in combination with ibuprofen and aspirin (acetylsalicylic acid). Although clinical uncertainty exists regarding the extrapolation of these data, regular or long-term ibuprofen use may reduce the cardioprotective effects of low-dose aspirin. Although there are no data for dexibuprofen, it is reasonable to assume that there is an interaction between dexibuprofen and low-dose aspirin similar to ibuprofen.

4. Adverse reactions
1) Shock: In rare cases, shock symptoms may appear, so observe thoroughly and if symptoms such as nausea, chills, difficulty breathing, or decreased blood pressure appear, stop administration and take appropriate measures.
2) Blood: In rare cases, blood disorders such as aplastic anemia, hemolytic anemia, decreased granulocytosis, decreased platelet function, decreased platelet function (prolonged bleeding time), and increased eosinophilia may occur. Therefore, conduct sufficient observation, including blood tests, and immediately discontinue administration if any abnormalities are found.
3) Digestive system: In rare cases of peptic ulcer, gastrointestinal bleeding, perforation, ulcerative colitis, bloody stool, gastritis, pancreatitis, etc., discontinue administration. Additionally, symptoms such as loss of appetite, nausea, vomiting, abdominal pain, indigestion, diarrhea, stomach discomfort, or very rarely dry mouth, stomatitis, abdominal distension, and constipation may appear.
4) Skin: In rare cases, Stevenson-Johnson syndrome (mucocutaneous ocular syndrome) or Riel syndrome (toxic epidermal necrolysis), drug rash accompanied by an unknown increase in eosinophils and systemic syndrome (DRESS syndrome), and acute generalized erythroderma pustulosis (AGEP) may occur. In these cases, discontinue administration.
5) Liver: In rare cases, jaundice, GOT, GPT, and AL-P elevation may occur.
6) Hypersensitivity: In rare cases, asthma attacks, hives, eczema, purpura, and sometimes rashes and itching may occur. In such cases, discontinue administration.
7) Sensory system: In rare cases, visual impairment such as ignoring or darkening may occur, so in such cases, discontinue administration. Additionally, in rare cases, hearing loss, tinnitus, and taste abnormalities may occur.
8) Mental nervous system: As aseptic meningitis has been rarely reported, if symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately discontinue administration and consult a doctor. In particular, administer with caution to patients with autoimmune diseases (SLE, MCTD).
9) Circulatory system: In rare cases, decreased blood pressure, increased blood pressure, and palpitations may occur.
10) Kidney: In rare cases, it may cause acute renal failure, so if symptoms such as oliguria or hematuria, elevated urine protein, BUN, or blood creatinine, or hyperkalemia appear in the test results, discontinue administration and take appropriate measures. Decreased urine output, systemic edema, and accompanying shortness of breath and drowsiness may occur.
11) Cardiovascular system: Patients with heart failure may have an increased risk of acute pulmonary edema.
12) Others: Occasionally, periorbital edema and, in very rare cases, malaise, fever, and epistaxis may occur.
13) Domestic post-marketing surveillance results (syrup formulation)
- The results of post-marketing surveillance conducted on 654 and 469 patients over 4 years for re-examination in Korea are as follows.
A) As a result of a post-marketing survey conducted on 654 patients, the adverse event rate was reported to be 0.61% (4 patients/654 patients, 4 cases) regardless of causal relationship. Fussiness, facial swelling, indigestion, and itching each occurred at 0.15% (1 person/654 people, 1 case).
The occurrence rate of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 0.46% (3 people/654 people, 3 cases), with irritability, facial edema, and indigestion each at 0.15% (1 person/654 people, 1 case). Unexpected adverse drug reactions were reported as irritability in 0.15% (1/654 people, 1 case).
Adverse events voluntarily reported during the domestic post-marketing surveillance period included one case of anaphylactic shock and one case of rash. Since these were reported from a population of uncertain size, it is difficult to estimate their frequency and causal relationship with this drug.
B) As a result of a post-marketing survey conducted on 469 patients, the adverse event incidence rate was reported to be 1.07% (5/469 patients, 5 cases) regardless of causal relationship. Diarrhea was found to be 0.85% (4 people/469 people, 4 cases), vomiting was 0.21% (1 person/469 people, 1 case), and no adverse drug reactions were reported. Among these, no serious or unexpected adverse events were reported.

5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following.
① Patients who take this drug for a long period of time should regularly conduct clinical tests (urinalysis, blood tests such as complete blood count (CBC) and physicochemical tests, liver function tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If necessary, blood coagulation tests (when antipyretic coagulants are administered), blood potassium concentration tests (when potassium retaining agents are administered), or blood lithium concentration tests are regularly performed. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
② Consider treatments other than drug therapy.
4) When using for acute diseases, consider the following:
① Administer considering the degree of acute inflammation, pain, and fever.
② In principle, long-term administration of the same drug should be avoided.
③ If there is a causative treatment, implement it.
④ In case of long-term administration, in principle, it is administered within 5 days.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Symptoms such as excessive decrease in body temperature, collapse, and cooling of extremities may occur, so pay close attention to the patient's condition after administration, especially in infants, children, the elderly, or patients with consumptive diseases accompanied by high fever.
6) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions. When using this drug for inflammation caused by infection, it should be administered with caution, along with an appropriate antibacterial agent and sufficient observation.
7) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
8) Hypertension: Non-steroidal anti-inflammatory drugs, including this drug, may cause hypertension or worsen existing hypertension, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
9) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
10) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal dysfunction, liver dysfunction, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
11) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
12) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values ​​may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
13) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
14) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
15) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
16) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients.
17) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.

6. Interaction
1) Do not administer in combination with other non-steroidal anti-inflammatory drugs (NSAIDs) as the risk of adverse reactions such as gastrointestinal adverse reactions and gastrointestinal bleeding may increase.
2) When used together with glucocorticoids and alcohol, there is a risk of adverse gastrointestinal reactions and gastrointestinal bleeding, so administer with caution.
3) When administered together with digoxin and phenytoin, plasma concentration may increase, so administer with caution.
4) When co-administered with probenecid or sulfinpyrazone, its effect may be reduced and excretion of dexibuprofen may be delayed, so administer with caution.
5) When administered in combination with sulfonylurease, the blood sugar lowering effect may be increased.
6) When administered in combination with diuretics or antihypertensive agents, the effectiveness may be reduced, so administer with caution.
7) ACE inhibitors: There have been reports that the antihypertensive effect of ACE inhibitors may be reduced by non-steroidal anti-inflammatory drugs, so this interaction should be kept in mind when administering this drug and ACE inhibitors together.
8) Furosemide
① As a result of clinical trials and post-marketing surveillance, it was confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. During concomitant administration of these drugs and nonsteroidal anti-inflammatory drugs, patients should be closely monitored for symptoms of renal impairment and signs of renal failure.
② When administered in combination with furosemide, its action may be reduced, so administer with caution.
9) Aspirin
① There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
② When administered together with aspirin, the action of this drug and other non-steroidal anti-inflammatory analgesics may be reduced.
10) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering NSAIDs and lithium, signs of lithium toxicity should be carefully observed.
11) Methotrexate: Concurrent administration with nonsteroidal anti-inflammatory drugs (NSAIDs) delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered in combination with high doses of methotrexate used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate.
12) Coumarin-based anticoagulants (warfarin, etc.)
① With regard to gastrointestinal bleeding, warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
② When coadministered with coumarin-based anticoagulants, its action may be enhanced, so administer with caution, such as reducing the dose.

7. Administration to pregnant women
1) In animal experiments, metabolic toxicity (inhibition of the number of implantations and survival at high doses was observed) has been reported, and there have been reports of persistent fetal circulation (PEO) occurring with other antipyretic, analgesic, and anti-inflammatory drugs, so it is advisable not to administer this drug to pregnant women or women who may be pregnant.
2) There is no clinical data on administering this drug to pregnant women. In experiments in which it was administered to rats at the end of pregnancy, constriction of the fetal ductus arteriosus was reported. Like other non-steroidal anti-inflammatory drugs, this drug should be avoided, especially in the latter stages of pregnancy, because it may cause premature closure of the fetus's ductus arteriosus.
3) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after approximately 20 weeks of pregnancy may cause abnormalities in fetal renal function, resulting in oligohydramnios and, in some cases, neonatal renal failure. Although oligohydramnios has been uncommonly reported within 48 hours of starting nonsteroidal anti-inflammatory drugs (NSAIDs), this side effect usually appears days to weeks after administration. Oligohydramnios is usually reversible upon discontinuation of treatment, but this is not always the case. If oligohydramnios persists, complications (e.g., limb contractures and delayed lung maturation) may occur. Some post-marketing cases of impaired neonatal renal function have required invasive procedures such as exchange transfusion or dialysis. If administration of this drug is necessary during the 20th to 30th week of pregnancy, the lowest effective dose should be used for the shortest period of time and if the administration time exceeds 48 hours, ultrasound monitoring of amniotic fluid should be considered. If oligohydramnios occurs, discontinue this drug and follow-up according to medical guidelines.
4) In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased the survival rate of pups.

8. Administration to nursing mothers
Since transfer to breast milk has been reported, there is concern that serious adverse reactions may occur in infants. Therefore, considering the importance of drug administration to nursing mothers, breastfeeding or drug administration should be discontinued.

9. Administration to children
1) Safety and efficacy for newborns and infants under 6 months of age have not been established.
2) For children weighing less than 30 kg, the daily dose should not exceed 300 mg.
3) For children, administer with caution in the minimum necessary amount and pay particular attention to the occurrence of adverse reactions.

10. Administration to elderly people
Elderly people are prone to adverse reactions, so begin administration in small quantities and administer the minimum amount necessary, and administer carefully while observing the patient's condition, paying particular attention to the occurrence of adverse reactions. (Refer to general precautions)

11. Effect on clinical test values
Rarely, increases in urea nitrogen, transaminase, and alkaline phosphatase, decreases in hemoglobin and hematocrit, decreased platelet aggregation, and prolonged bleeding time may occur.

12. Treatment in case of overdose
Perform gastric lavage or induce vomiting as quickly as possible.

13. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Store in a light-proof, airtight container at room temperature (15~25℃)

6. Packaging unit
500mL/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 5items

No.Product NameDetailsDate of ChangeDownload
5Dexidifen SyrupDosage, usage precautions2026.02.05PDFDexidefen syrup unified adjustment (draft) and change comparison table_Usage dosage, four weeks.pdf
4Dexidifen SyrupPrecautions for use2026.01.02PDF0087_201708249_Dexidefen syrup_Precautions for use.pdf
3Dexidifen SyrupPrecautions for use2025.03.18PDF0089_201708249_Precautions for use_Dexidefen syrup.pdf
2Dexidifen SyrupPrecautions for use2024.05.22PDFDexidefen syrup_Precautions for use.pdf
1Dexidifen SyrupPrecautions for use2023.10.02PDF0101_201708249_Precautions for use (Dexidefen syrup).pdf